OncLive TV

Adanma Ayanambakkam, MD, MS, discusses efficacy data from the phase 1a/1b FIT-001 trial.

Adanma Ayanambakkam, MD, MS, discusses the mechanism of action of darlifarnib in ccRCC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, note data from a study of PD-L1 expression as a marker of response to TKIs in EGFR-mutated NSCLC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the role for PD-L1 expression as a biomarker for treatment response in EGFR-mutant NSCLC.

Rena D. Callahan, MD, discusses the implications of the NATALEE trial of adjuvant ribociclib plus endocrine therapy in HR-positive early breast cancer.

Vinayak Venkataraman, MD, spotlights a focus-group study identifying mobility, autonomy, and supportive care gaps in AYA patients with sarcoma.

Taigo Kato, MD, PhD, discusses the use of ctDNA-guided therapy in patients with RCC.

Peter C. Enzinger, MD, discusses the significance of Claudin 18.2 and HER2 as actionable biomarkers in gastroesophageal cancer.

Fangdi Sun, MD, discusses how biomarker testing can help navigate the complexity of treatment decision-making across the spectrum of head and neck cancers.

Taigo Kato, MD, PhD, discusses future directions of MONSTAR-SCREEN-3 and how data from the study can be applied to clinical practice.

Taigo Kato, MD, PhD, discusses the background of the MONSTAR-SCREEN-3 in resectable RCC and the key findings from the study.

Michael Schweizer, MD, discusses the mechanism of action of mevrometostat and early-phase data with the agent in mCRPC.

Alicia Morgans, MD, MPH, discusses safety concerns and AE management with mevrometostat in mCRPC.

Lore Gruenbaum, PhD, discusses developments in mantle cell lymphoma management that she has her eye on and critical unmet needs in the field.

R. Lor Randall, MD, FACS, discusses the rationale of a meta-analysis comparing IM nailing and EP reconstruction for patients with bone metastases.

Meghan R. Flanagan, MD, MPH, discusses the multidisciplinary complexities that arise when trying to coordinate de-escalated breast cancer care.

Meghan R. Flanagan, MD, MPH, notes takeaways from a multidisciplinary tumor board discussion on how genomic assays can guide treatment decisions for DCIS.

Aaron Gerds, MD, MS, details the rationale for targeting CALR mutations in the management of myeloproliferative neoplasms

Luhua (Michael) Wang, MD, discusses the significance of the full FDA approval of brexu-cel in relapsed/refractory mantle cell lymphoma.

Dallas Gallagher, DNP, FNP-C, AOCNP, discusses the importance of a patient-focused approach when managing the emotional weight of a pancreatic cancer diagnosis.

Bradley Monk, MD, discusses the final analysis of the phase 3 KEYNOTE-B96 trial in platinum-resistant recurrent ovarian cancer.

Alexander Olawaiye, MD, discusses the final overall survival data from the phase 3 ROSELLA trial in platinum-resistant ovarian cancer.

Manish Patel, DO, discusses future directions for investigating hormonal plus immune therapies for the treatment of patients with salivary gland cancer.

Manish Patel, DO, discusses AEs seen with ADT plus pembrolizumab in patients with advanced-stage, androgen receptor–positive salivary gland cancer.

Sun Yang, MD, discusses the activity of frontline cadonilimab plus chemotherapy in patients with recurrent/advanced endometrial carcinoma.

Bhavana Pothuri, MD, discusses phase 2 data with trastuzumab pamirtecan (DB-1303/BNT323) in pretreated patients with HER2-expressing endometrial cancer.

Rana R. McKay, MD, discusses findings from the phase 4 OPTYX trial of real-world relugolix in advanced prostate cancer.

Manish Patel, DO, discusses response rates seen with ADT in combination with pembrolizumab in advanced, androgen receptor–positive salivary gland cancer.

Rana R. McKay, MD, discusses, the study design and baseline patient characteristics of the OPTYX trial of relugolix in advanced prostate cancer

Tara Graff, DO, details the role of CAR T-cell therapy in the relapsed/refractory diffuse large B-cell lymphoma treatment paradigm.